Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Giagulli, CinziaNoerder, Miriam
Avolio, Manuela
Becker, Pablo D
Fiorentini, Simona
Guzman, Carlos A
Caruso, Arnaldo
Issue Date
2009-11
Metadata
Show full item recordAbstract
Mucosal dendritic cells (DCs) are very important in the process of antigen presentation to T cells, playing a key role in the induction of primary and secondary immune responses. Pidotimod is a synthetic substance capable of modulating immune cell functions, but the effect of pidotimod on human DCs has not been investigated yet. Here we demonstrate the ability of pidotimod to induce DC maturation and up-regulate the expression of HLA-DR and co-stimulatory molecules CD83 and CD86, which are fundamental for communication with adaptative immunity cells. Pidotimod also stimulated DCs to release high amounts of pro-inflammatory molecules such as MCP-1 and TNF-alpha cytokines and to drive T cell proliferation and differentiation towards a Th1 phenotype. Moreover, we demonstrate that pidotimod in vivo promotes strong and specific humoral and cellular immune response when co-administered intranasally with a model antigen. Taken together our data suggest the possibility to use pidotimod as adjuvant molecule to facilitate the activation of the innate immune system as well as to promote an effective mucosal and systemic immune response.Citation
Pidotimod promotes functional maturation of dendritic cells and displays adjuvant properties at the nasal mucosa level. 2009, 9 (12):1366-73 Int. Immunopharmacol.Affiliation
Department of Experimental and Applied Medicine, Section of Microbiology, University of Brescia, Medical School, Brescia, Italy.Journal
International immunopharmacologyPubMed ID
19712757Type
ArticleLanguage
enISSN
1878-1705ae974a485f413a2113503eed53cd6c53
10.1016/j.intimp.2009.08.010
Scopus Count
The following license files are associated with this item:
Related articles
- Human CD8⁺ T cells drive Th1 responses through the differentiation of TNF/iNOS-producing dendritic cells.
- Authors: Chong SZ, Wong KL, Lin G, Yang CM, Wong SC, Angeli V, Macary PA, Kemeny DM
- Issue date: 2011 Jun
- Evidence for the role of interferon-alfa production by dendritic cells in the Th1 response in celiac disease.
- Authors: Di Sabatino A, Pickard KM, Gordon JN, Salvati V, Mazzarella G, Beattie RM, Vossenkaemper A, Rovedatti L, Leakey NA, Croft NM, Troncone R, Corazza GR, Stagg AJ, Monteleone G, MacDonald TT
- Issue date: 2007 Oct
- Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activation.
- Authors: Ohmura M, Yamamoto M, Tomiyama-Miyaji C, Yuki Y, Takeda Y, Kiyono H
- Issue date: 2005 Jul
- Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants.
- Authors: Sokolovska A, Hem SL, HogenEsch H
- Issue date: 2007 Jun 6
- Muramyl dipeptide-Lys stimulates the function of human dendritic cells.
- Authors: Todate A, Suda T, Kuwata H, Chida K, Nakamura H
- Issue date: 2001 Nov